Effectiveness of the Biomarkers CK-18-M30 and FGF-21 in the Diagnosis of Metabolically Dysfunctional-Associated Steatotic Liver Disease in Noninvasive Assessment of Liver Fibrosis among Type 2 Diabetes Patients

Read full text Summarise with VIRAT
Authors: Salah Abusnana, Eman Elazrag, Bashair M. Mussa, Mohsin Sulaiman
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: A growing global health concern involving fat accumulation in over 5% of liver cells, unrelated to alcohol, medications, or other liver diseases. Rising incidence demands noninvasive diagnostic methods. Objective: This study evaluates serum biomarkers CK18-M30 and FGF21 for detecting MASLD in type 2 diabetes patients, assesses advanced fibrosis using the FIB-4 index, and identifies primary associated risk factors. Methods: A multicenter, prospective, cross-sectional study was conducted involving 140 T2D patients across various centers in the UAE. Participants were categorized based on the presence or absence of MASLD, as indicated by abdominal ultrasound. Fasting overnight, blood samples were collected to test serum CK18-M30 and FGF-21. The FIB-4 index was used to evaluate liver fibrosis prevalence among patients, and key risk factors associated with MASLD were analyzed. Results: The cohort consisted of 140 T2D patients with an average age of 62.5 ± 8.4 years, with a higher proportion of females (56.4%) compared to males (43.6%), and 55% classified as obese (BMI ≥ 30 kg/m 2 ). Dyslipidemia and hypertension were prevalent at rates of 96 and 84.3%, respectively. The MAFLD group exhibited significantly lower HDL levels (41.7%) compared to the non-MASLD group (18.9%). FGF-21 levels were significantly higher in the MASLD group, demonstrating superior diagnostic performance with high sensitivity (89.5%) and specificity (92.1%). The FIB-4 index indicated a low prevalence (2%) of advanced liver fibrosis within the cohort. Conclusion: The present study highlighted the diagnostic effectiveness of the biomarkers CK-18-M30 and FGF-21, with FGF-21 demonstrating superior accuracy for MASLD detection in T2D patients. Obesity and BMI levels were markedly linked with MASLD occurrence among T2D patients. This research study highlights the critical role of early screening and management of liver fibrosis and MASLD in patients with T2D. Publication History Article published online: 25 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Fields of Study & Subjects

Liver Disease Diagnosis and Treatment Chronic Kidney Disease and Diabetes Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
Ibnosina Journal of Medicine and Biomedical Sciences
Volume
18
Publication date
1 March 2026
Language
EN